John Pollack, MD, discusses gene therapy advancements for retinal diseases.
John Pollack, MD
Advertisement
Illinois Retina Associates and Assistant Professor, Ophthalmology, Rush University
Articles by John Pollack, MD
NT-501 previously received orphan drug and fast track status from the FDA and Neurotech will pursue approval in late 2022.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
FDA Picks Abeona’s XLRS Gene Therapy ABO-503 for RDEA Pilot Program
2
BLA for Rocket’s LAD-I Gene Therapy Under Review by FDA Again
3
Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation
4
